Jacos Pharmaceuticals has unveiled its annual financial results for 2025, revealing a total revenue of 53.5 million yuan for the year. Notably, the company managed to narrow its net loss to around 146 million yuan, marking a 6.25% decrease compared to the previous year. During 2025, Jacos Pharmaceuticals made significant strides in the realms of KRAS-targeted therapies and cutting-edge ADC platforms. Specifically, the KRAS G12C inhibitor, Gorelasib, secured marketing approval in China and was included in the National Reimbursement Drug List. Additionally, the company inked a collaboration deal with AstraZeneca for the pan-KRAS inhibitor, JAB-23E73, with a total value of $2.015 billion (inclusive of an initial payment of $100 million). Furthermore, the EGFR-KRAS G12Di tADC and HER2-STINGa iADC candidates progressed to the IND preparation stage. By the close of 2025, Jacos Pharmaceuticals' cash, cash equivalents, and bank credit facilities amounted to approximately 1.53 billion yuan, reflecting a positive balance of payments. The company anticipates that this balance will surpass 2 billion yuan in the first quarter of 2026 and is on track to achieve profitability.